U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07200102) titled 'Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma' on Sept. 22.
Brief Summary: The outcomes in patients with relapsed multiple myeloma refractory to triple-therapy (anti-CD38, immunomodulatory drugs (IMiD) and proteasome inhibitors (PI)) remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous T-cells to clear myeloma cells by targeting B-cell maturation antigen (BCMA). BCMA CAR-T therapy is not curative, and unlike autologous stem cell transplant, there is currently no standard for maintenance therapy post CAR-T which could potentially increase MRD ...